Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2019

Apr 02, 2019

SELL
$19.6 - $24.76 $23,324 - $29,464
-1,190 Closed
0 $0
Q4 2018

Jan 11, 2019

SELL
$13.65 - $21.8 $18,973 - $30,302
-1,390 Reduced 53.88%
1,190 $23,000
Q3 2018

Oct 16, 2018

BUY
$15.87 - $22.4 $40,944 - $57,791
2,580 New
2,580 $46,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.5B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track First Hawaiian Bank Portfolio

Follow First Hawaiian Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Hawaiian Bank, based on Form 13F filings with the SEC.

News

Stay updated on First Hawaiian Bank with notifications on news.